

Complex of C₆₀ fullerene with doxorubicin as promising agent in antitumor therapy

S. Prylutska¹, L. Skivka¹, G. Didenko², Yu. Prylutskyi¹, M. Evstigneev³,
G. Potebnya², R.R. Panchuk^{4*}, R.S. Stoika⁴, U. Ritter⁵, P. Scharff⁵

¹Taras Shevchenko National University of Kyiv, 64 Volodymyrska Str.,
01601 Kyiv, Ukraine

²R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
of NASU, Vasylykivska Str. 45, 03022 Kyiv, Ukraine

³Belgorod State University, Pobedy Str.85, 308015 Belgorod, Russia

^{4*}Institute of Cell Biology, NAS of Ukraine, 14-16 Drahomanov Str., 79005, Lviv,
Ukraine; E-mail: rpanchuk@ukr.net

⁵Technical University of Ilmenau, Institute of Chemistry and Biotechnology,
25 Weimarer Str., 98693 Ilmenau, Germany

The purpose of this work was to evaluate the effect of C₆₀ fullerene with antitumor drug doxorubicin (C₆₀+Dox) complex on the growth and metastasis of Lewis lung carcinoma and to perform a primary screening of the potential mechanisms of C₆₀+Dox complex action. The volume of tumor from male C57Bl/6 mice treated with the C₆₀+Dox complex was 1.4 times less than that in *control* untreated animals. The number of metastatic foci in animal lungs from the group treated with C₆₀+Dox complex was 2 times less than that in *control* untreated animals. Western blot analysis of tumor lysates revealed significantly decreased level of heat-shock protein 70 in animals treated with C₆₀+Dox complex. Moreover, the treatment of tumor-bearing mice was accompanied by the increase of cytotoxic activity of immune cells. Thus, the potential mechanisms of C₆₀+Dox complex antitumor effect are direct action on tumor cells by inducing cell death and by increasing of stress sensitivity as well as immunomodulating effect. The obtained results provide scientific basis for further application of C₆₀+Dox nanocomplexes as agents in cancer chemotherapy.